Investor Presentaiton
Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-
treated inoperable or metastatic hormone receptor-positive, HER2-
negative (HR+/HER2-) breast cancer:
Primary results from the randomised Phase 3 TROPION-Breast01 trial
Aditya Bardia, Komal Jhaveri,² Seock-Ah Im,³ Sonia Pernas,4 Michelino De Laurentiis, 5 Shusen Wang,6 Noelia Martínez Jañez,7 Giuliano Borges,³
David W. Cescon,9 Masaya Hattori, 10 Yen-Shen Lu, 11 Erika Hamilton, 12 Qingyuan Zhang, 13 Junji Tsurutani, 14 Kevin Kalinsky, 15 Lu Xu,16 Neelima
Denduluri,17 Hope S. Rugo, 18 Binghe Xu, 19* Barbara Pistilli20*
*Contributed equally
1Massachusetts General Hospital Cancer Center, Boston, MA, USA; 2Memorial Sloan Kettering Cancer Center, New York, NY, USA, and Weill Cornell Medical College, New York, NY, USA;
3Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea; 4Institut Català d'Oncologia,
IDIBELL, L'Hospitalet, Barcelona, Spain; 5Istituto Nazionale Tumori Napoli IRCCS "Fondazione Pascale", Napoli, Italy; 6Cancer Center of Sun Yet-sen University, Guangzhou, China; 'Ramón y
Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain; 8Catarina Pesquisa Clínica, Santa Catarina, Brazil; 9Princess Margaret Cancer Centre/UHN,
Toronto, ON, Canada; 10Aichi Cancer Center, Nagoya, Japan; 11National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan; 12Sarah Cannon Research
Institute / Tennessee Oncology, Nashville, TN, USA; 13Harbin Medical University Cancer Hospital, Harbin, China; 14Showa University Hospital, Tokyo, Japan; 15Winship Cancer Institute at Emory
University, Atlanta, GA, USA; 16AstraZeneca, New York, NY, USA; 17AstraZeneca, Arlington, VA, USA; 18University of California San Francisco Comprehensive Cancer Center, San Francisco,
CA, USA; 19 National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China;
20 Gustave Roussy Cancer Center, Villejuif, France
Daiichi-Sankyo
23View entire presentation